The tablets are generic version of Janssen Pharmaceuticals Inc oral contraceptive Ortho Cyclen tablets
Drug firm Glenmark Pharmaceuticals said it has received final approval from the US health regulator for its generic contraceptive norgestimate and ethinyl estradiol tablets.
Glenmark Generics Inc, a subsidiary of Glenmark Generics has been granted final approval for their abbreviated new drug application (ANDA) by the US Food and Drug Administration (USFDA) for Norgestimate and Ethinyl Estradiol tablets in the strengths of 0.25 mg/0.035 mg, Glenmark Pharmaceuticals said in a statement.
The tablets are generic version of Janssen Pharmaceuticals Inc oral contraceptive Ortho Cyclen tablets.
Citing IMS Health data for the 12-month period ending December 2011, the company said norgestimate and ethinyl estradiol tablets of strength 0.25mg/0.035mg garnered total market sales of approximately $88 million.
The company currently has 79 generic products authorised for distribution in the US market and 39 ANDA’s pending approval with the USFDA, Glenmark said.
Today’s approval is Glenmark’s tenth female hormonal product authorised for distribution by the USFDA, it added.
In the late afternoon, Glenmark Pharmaceuticals was trading at around Rs308.05 per share on the Bombay Stock Exchange, 0.26% down from the previous close.
L &T Construction achieves 114MW of installations in a single year
L&T Construction has commissioned India’s largest solar photo voltaic based power plant (40 MWp) owned by Reliance Power Ltd at Dhursar Village, Jaisalmer district of Rajasthan. As the largest EPC player in solar power, L&T Construction executed the solar power plant from concept (including detailed design) to commissioning in 129 days. With the commissioning of this plant, L&T Construction has installed 114MW of utility scale solar PV power plants over the last fiscal–a benchmark in India’s solar EPC industry.
The solar PV power plant is equipped to supply more than 70 million units of clean and green energy to 75,000 households. The clean energy generated by the plant is expected to displace nearly 70,000 MT of CO2 annually.
The Solar PV power plant, which comprises more than 5,00,000 high output generating thin film technology based Solar PV modules and thirteen 3.5 MVA power transformers to generate 40MWp, is spread across 350 acres. The thin film Solar PV modules for the project were procured by Reliance Power; while L&T’s scope of work included complete design, engineering, procurement and construction of 40 MWp solar power plant, including construction of a 5km 33 kV double circuit transmission line.
In the early afternoon, Larsen & Toubro was trading at around Rs1,305 per share on the Bombay Stock Exchange, 3% down from the previous close.
Srinivasan qualified as a Fellow of the Institute of Actuaries, UK in 2004
HDFC Life has appointed Srinivasan Parthasarthy as its chief and appointed actuary.
Mr Srinivasan joined HDFC Life in 2011 from Canara HSBC Life Insurance with 18 years of experience in life insurance and pensions in both India and the UK. He was one of the two candidates from Asia to be selected by the then president of the Institute of Actuaries, UK in the year 2000 to work for Watson Wyatt, UK, where he provided a range of consultancy services to clients on various aspects of company pension schemes. Then he moved on to work with Aviva UK where he worked in different areas including pricing, reporting and stochastic modelling, before being seconded to Aviva India. His key achievement at Aviva India was leading the transition from TEV to MCEV reporting.
Srinivasan qualified as a Fellow of the Institute of Actuaries, UK in 2004 and became a Fellow of the Institute of Actuaries of India in 2008.